๐Ÿ“œ Post with us on Reddit
๐Ÿ“ Create a new article
๐Ÿญ Create a company page
๐Ÿ‡ฌ๐Ÿ‡ง - in English
๐Ÿ‡ซ๐Ÿ‡ท - en Franรงais (FR)
๐Ÿ‡ต๐Ÿ‡น - em Portuguรชs (PT)
๐Ÿ‡ฉ๐Ÿ‡ช - auf Deutsch (DE)
๐Ÿ‡ฏ๐Ÿ‡ต - ๆ—ฅๆœฌ่ชžใง (JA)
Sponsored articles

You can edit almost every page by Creating an account and confirming your email.

Han-Oh Park

From EverybodyWiki Bios & Wiki


Han-Oh Park
Native name๋ฐ•ํ•œ์˜ค
Born (1962-05-16) May 16, 1962 (age 64)
Inje, Gangwon Province, Republic of Korea
๐Ÿณ๏ธ NationalitySouth Korean
๐ŸŽ“ Alma materSeoul National University (B.S. Chemistry)
KAIST (M.S. Chemistry, Ph.D. Chemistry)
Chungnam National University (Honorary Doctorate in Entrepreneurship)
๐Ÿ’ผ Occupation
Biochemist, Entrepreneur
Known forFounder of Bioneer Corporation

Han-Oh Park (Korean: ๋ฐ•ํ•œ์˜ค; born May 16, 1962) is a South Korean biochemist and entrepreneur. He is the founder, CEO, and Chairman of Bioneer Corporation, a South Korean biotechnology company.[1]
Park has contributed to the development and commercialization of technologies related to DNA and RNA synthesis, molecular diagnostics, RNAi therapeutics, cosmeceuticals, and the microbiome.[2][3][4]

Education

Park earned a B.S. in Chemistry from Seoul National University in 1984. He earned an M.S. (1986) and Ph.D. (1992) in Chemistry from KAIST, where his research on oligonucleotide synthesis and enzyme engineering[5] laid the foundation for his later work in RNAi therapeutics and diagnostics.[6] Park also received an Honorary Doctorate in Entrepreneurship from Chungnam National University in South Korea.[7]

Career

Before founding Bioneer Corporation, Han-Oh Park was a researcher at the Genetic Engineering Center (now Korea Research Institute of Bioscience and Biotechnology (KRIBB)), where he worked on genetic and diagnostic technologies.[8]

In 1992, Han-Oh Park founded Bioneer Corporation, recognized as Koreaโ€™s first biotechnology company.[9] Under his leadership, Bioneer expanded its business to include life sciences, molecular diagnostics, RNA interference (RNAi) therapeutics, cosmeceuticals, and the microbiome.[10]

Park also played a key role in establishing subsidiaries such as siRNAgen Therapeutics (Founder & CEO Han-Oh Park) and AceBiome (Founder & CEO Myeong Hee Kim), supporting the development of RNAi-based therapeutics and probiotics, respectively.[11]

Research and Achievement

Commercialization of Advanced Genetic and Molecular Diagnostic Technologies in South Korea

Han-Oh Park was involved in introducing and commercializing Nobel Prize-winning technologies in South Korea, including DNA synthesis, Polymerase Chain Reaction (PCR), sequencing, small interfering RNA (siRNA), and microRNA (miRNA). Through Bioneer Corporation, these technologies have become widely accessible for research and diagnostics, contributing to the growth of the domestic biotechnology industry.[12][13][14]
Parkโ€™s efforts to commercialize Polymerase Chain Reaction (PCR) technology led to the development and expansion of molecular diagnostic techniques, and this progression is recognized as having played a significant role in strengthening South Koreaโ€™s molecular diagnostics capabilities.[15][16]

Invention of the siRNA Therapeutics Platform Technology

Han-Oh Park is credited with conceiving the core idea behind the Self-Assembled-Micelle inhibitory RNA (SAMiRNA) platform, an RNA interference (RNAi) technology designed to improve the delivery and stability of small interfering RNA (siRNA) therapeutics. Together with a team of researchers at Bioneer, he co-invented and secured multiple patents for the technology.[17]
Under Parkโ€™s leadership, siRNAgen Therapeutics is actively engaged in new drug development, including the development of SRN-001, a candidate therapeutic for fibrosis.[18][19]

Development of Novel Probiotic Strain

Park also led the development of Lactobacillus gasseri BNR17, a probiotic strain isolated from human breast milk. Clinical studies have shown that this strain can reduce body weight, visceral fat, waist circumference, and BMI in obese adults.[20]
It has been officially recognized by the Korean Ministry of Food and Drug Safety for its body fat reduction functionality.[21] This strain has been patented in over 10 countries as a probiotic with anti-obesity and anti-diabetic effects.[22] The strain has been commercialized through AceBiome, expanding its global market reach.[23]

Development of Numerous Patents

Park has developed and published numerous patents across a broad range of biotechnology fields, including gene analysis, gene synthesis, drug development, probiotics, and cosmeceuticals. In addition to his patent portfolio, Park has authored numerous scientific publications in these areas. Representative publications include:

  • Park, HO. et al. "DNA synthesis and biological security." Nature Biotechnology 25(6): 627โ€“629 (2007).[24]
  • Park, HO. et al. "Analysis of a genome-wide set of gene deletions in the fission yeast Schizosaccharomyces pombe." Nature Biotechnology 28(6): 617โ€“623 (2010).[25]
  • Park, HO. et al. "Stc1: a critical link between RNAi and chromatin modification required for heterochromatin integrity." Cell 140(5): 666โ€“677 (2010).[26]
  • Park, HO. et al. "Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis." Journal of Biological Chemistry 291(12): 6433โ€“6446 (2016).[27]
  • Park, HO. et al. "Safety pharmacology of self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG), a novel siRNA nanoparticle platform." Toxicology Reports 8: 839โ€“845 (2021).[28]
  • Park, HO. et al. "Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia." Scientific Reports 12(1): 1607 (2022).[29]

Parkโ€™s patents and publications are listed in databases such as ORCID and Google Patents.[30][31]

Awards and honors

  • Gold Tower Order of Industrial Service Merit (2021) โ€“ awarded by the Republic of Korea for contributions to molecular diagnostics and export competitiveness.[3]
  • POSCO TJ Park Prize, Technology Prize (2023) โ€“ POSCO TJ Park Foundation; awarded for contributions to technology development and commercialization advancing Koreaโ€™s bio industry.[32]
  • FACS Award for Distinguished Contribution to Economic Advancement (2025) โ€“ Federation of Asian Chemical Societies; awarded for outstanding contributions to industrial and economic development in the Asia-Pacific region.[4]

References


This article "Han-Oh Park" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Han-Oh Park. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

  1. โ†‘ "Park Han-oh - CEO & Chairman". KoreaWho. 2025-07-13. Retrieved 2025-07-15.
  2. โ†‘ "Daejeon TechnoPark". HeraldK. 2021-02-26. Retrieved 2025-07-02.
  3. โ†‘ 3.0 3.1 "๋ฐ•ํ•œ์˜ค ๋ฐ”์ด์˜ค๋‹ˆ์•„ ๋Œ€ํ‘œ, ์‚ฐ์—…ํ›ˆ์žฅ ๊ธˆํƒ‘ ์ˆ˜์ƒ". ์—ฐํ•ฉ๋‰ด์Šค (in ํ•œ๊ตญ์–ด). 2021-12-16. Retrieved 2025-07-01.
  4. โ†‘ 4.0 4.1 "๋ฐ•ํ•œ์˜ค ๋ฐ”์ด์˜ค๋‹ˆ์•„ ํšŒ์žฅ, 'FACS ๊ฒฝ์ œ๋ฐœ์ „ ๊ณต๋กœ์ƒ' ์ˆ˜์ƒ". Maeil Business Newspaper (in ํ•œ๊ตญ์–ด). 2025-06-20. Retrieved 2025-07-03. The official award name is "FACS Award for Distinguished Contribution to Economic Advancement 2025." The news article refers to it as "Distinguished Contribution to Economic Development Award."
  5. โ†‘ Park, Han-Oh (1992). "Glycosidic bond formation by glycosidase in organic solvent" (Doctoral dissertation). Korea Advanced Institute of Science and Technology.
  6. โ†‘ "๊น€์ฒ ํ™˜ยท๋ฐ•ํ•œ์˜คยท๋ฐฑ์›ํ•„ ๋“ฑ KAIST '์ž๋ž‘์Šค๋Ÿฐ ๋™๋ฌธ์ƒ'". ํ—ฌ๋กœ๋””๋”” (in ํ•œ๊ตญ์–ด). 2017-01-11. Retrieved 2025-07-03.
  7. โ†‘ "์ถฉ๋‚จ๋Œ€ ๋™๋ฌธ ๋ฐ•ํ•œ์˜ค ๋Œ€ํ‘œ, ๋ฐ”์ด์˜ค๋‹ˆ์•„ ํ†ตํ•ด K-๋ฐ”์ด์˜ค ์„ ๋„". Chungnam National University (in ํ•œ๊ตญ์–ด). 2023-11-28.
  8. โ†‘ "ํ•œ๊ตญ์ƒ๋ช…๊ณตํ•™์—ฐ๊ตฌ์›_์‚ฐ์—…๊ณ„๋ฅผ ๋น›๋‚ธ KRIBBian". KRIBB (in ํ•œ๊ตญ์–ด). 2022-12-22. Retrieved 2025-07-03.
  9. โ†‘ "ํ•œ๊ตญ ๋ฐ”์ด์˜ค๋ฒค์ฒ˜์˜ ํƒœ๋™๊ณผ ์„ฑ์žฅ". STEPI (in ํ•œ๊ตญ์–ด). ๊ณผํ•™๊ธฐ์ˆ ์ •์ฑ…์—ฐ๊ตฌ์›. 2017-12-29. Retrieved 2025-07-08.
  10. โ†‘ "2024๋…„ ์‚ฌ์—…๋ณด๊ณ ์„œ" (in ํ•œ๊ตญ์–ด). Financial Supervisory Service (DART). 2025-03-21. Retrieved 2025-07-15.
  11. โ†‘ "์ถฉ๋‚จ๋Œ€, ๋ฐ”์ด์˜ค๋‹ˆ์•„ ๋ฐ•ํ•œ์˜ค ๋Œ€ํ‘œ์— ๋ช…์˜ˆ ์ฐฝ์—…ํ•™๋ฐ•์‚ฌ ํ•™์œ„" (in ํ•œ๊ตญ์–ด). Daily Hankook. 2023-04-26. Retrieved 2025-07-15.
  12. โ†‘ "Han-Oh Park - President, Founder and CEO, Bioneer, South Korea". Pharmaboardroom. 2019-11-02. Retrieved 2025-07-14.
  13. โ†‘ "[K๋ฐ”์ด์˜ค๋ฆฌ๋”] ๋ฐ•ํ•œ์˜ค ๋ฐ”์ด์˜ค๋‹ˆ์•„ ํšŒ์žฅ "PCRยทDNA ํ•ฉ์„ฑ 30๋…„ ์™ธ๊ธธ๋กœ ์„ธ๊ณ„ 1๋“ฑโ€ฆ ๋‹ค์Œ์€ siRNA ์น˜๋ฃŒ์ œ"". ์กฐ์„ ๋น„์ฆˆ (in ํ•œ๊ตญ์–ด). 2022-08-28. Retrieved 2025-07-08.
  14. โ†‘ "Bioneer Represents the Cutting Edge of Biotechnology". Korea IT Times. 2013-01-21. Retrieved 2025-07-14.
  15. โ†‘ "์‹ ์ข…ํ”Œ๋ฃจ ๋•(?)โ€ฆํŠน์ˆ˜ ๋ˆ„๋ฆฌ๋Š” ๋Œ€๋•ํŠน๊ตฌ ๋ฒค์ฒ˜". ๋””์ง€ํ„ธํƒ€์ž„์Šค (in ํ•œ๊ตญ์–ด). 2009-11-09. Retrieved 2025-07-08.
  16. โ†‘ "Bioneer". Maeil Business Newspaper. 2024-09-24. Retrieved 2025-07-14.
  17. โ†‘ "US10030243B2: Nanoparticle type oligonucleotide structure having high efficiency and method for preparing same". Google Patents. USPTO. 2018-07-24. Retrieved 2025-07-08.
  18. โ†‘ "๋ฐ”์ด์˜ค๋‹ˆ์•„ ์žํšŒ์‚ฌ ์จ๋‚˜์  , ํŠน๋ฐœ์„ฑํ์„ฌ์œ ์ฆ ์‹ ์•ฝ 'SRN-001' ๊ฐœ๋ฐœ ์ง‘์ค‘". ๋ฐ”์ด์˜คํƒ€์ž„์ฆˆ (in ํ•œ๊ตญ์–ด). 2024-04-18. Retrieved 2025-07-14.
  19. โ†‘ Lee Sang-gyu (2024-06-25). "Bioneer marks milestone with phase 1a clinical results of SRN-001, a next-generation new drug candidate". Maeil Business Newspaper (MK). Retrieved 2025-07-14. SRN-001 is the first case where Bioneer's SAMiRNA platform was applied to humans.
  20. โ†‘ Jung, Seung-Pil; Lee, Keun-Mi; Kang, Ji-Hee; Yun, Sung-Il; Park, Han-Oh; Moon, Yong; Kim, Jong-Yeon (2013). "Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial". Korean Journal of Family Medicine. 34 (2): 80โ€“89. doi:10.4082/kjfm.2013.34.2.80. PMC 3611107. PMID 23560206.
  21. โ†‘ "๊ธฐ๋Šฅ์„ฑ์›๋ฃŒ์ธ์ • ์ œ2014-5ํ˜ธ: Lactobacillus gasseri BNR17" (in ํ•œ๊ตญ์–ด). Functional Food Material Information System (FMIS). 2014. Retrieved 2025-07-15.
  22. โ†‘ "US Patent 8,309,076: Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation". Google Patents. 2012-11-13. Retrieved 2025-07-14.
  23. โ†‘ "Korean probiotics make global debut". Maeil Business Newspaper. 2022-03-22. Retrieved 2025-07-14.
  24. โ†‘ Bรผgl, Hans; Danner, John P.; Molinari, Robert J.; Mulligan, John T.; Park, Han-Oh; Reichert, Bas; Roth, David A.; Wagner, Ralf; Budowle, Bruce; Scripp, Robert M.; Smith, Jenifer A. L.; Steele, Scott J.; Church, George; Endy, Drew (2007). "DNA synthesis and biological security". Nature Biotechnology. 25 (6): 627โ€“629. doi:10.1038/nbt0607-627. PMID 17557094.
  25. โ†‘ Kim, D.; Hayles, J.; Kim, D. U.; Wood, V.; Park, Han-Oh; Won, M.; Yoo, H. S.; Duhig, T.; Nam, M.; Palmer, G.; Han, S.; Jeffery, L.; Baek, S. T.; Lee, H.; Shim, Y. S.; Lee, M.; Kim, H. M.; Park, H. O.; Kim, L. (2010). "Analysis of a genome-wide set of gene deletions in the fission yeast Schizosaccharomyces pombe". Nature Biotechnology. 28 (6): 617โ€“623. doi:10.1038/nbt.1628. PMC 3962850. PMID 20473289.
  26. โ†‘ Bayne, E. H.; White, S. A.; Kagansky, A.; Bijos, D. A.; Sanchez-Pulido, L.; Hoe, K. L.; Mashiko, T.; Kowalik, K. M.; McCann, J. A.; Porter, A.; Matsuda, A.; Nozaki, N.; Richardson, W.; Shevchenko, A.; Enright, A. J.; Aravind, L.; Takahashi, K.; Allshire, R. C. (2010). "Stc1: a critical link between RNAi and chromatin modification required for heterochromatin integrity". Cell. 140 (5): 666โ€“677. doi:10.1016/j.cell.2010.01.038. PMC 2875855. PMID 20211136.
  27. โ†‘ Yoon, Pyoung Oh; Park, Jin Wook; Lee, Chang-Min; Kim, Sung Hwan; Kim, Han-Na; Ko, Youngho; Bae, Seon Joo; Yun, Sungil; Park, Jun Hong; Kwon, Taewoo; Kim, Woo Seok; Lee, Jiyoung; Lu, Qing; Kang, Hye-Ryun; Cho, Won-Kyung; Elias, Jack A; Yang, Joo-Sung; Park, Han-Oh; Lee, Kyuhong; Lee, Chun Geun (2016). "Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis". Journal of Biological Chemistry. 291 (12): 6433โ€“6446. doi:10.1074/jbc.M115.693671. PMC 4813554. PMID 26817844.
  28. โ†‘ Kim, Tae Rim; Kim, Hyeon-Young; Kim, In-Hyeon; Kim, Ki Cheon; Ko, Youngho; Park, Jun Hong; Yun, Sungil; Lee, In-Chul; Kim, Sung-Hwan; Park, Han-Oh (2021). "Safety pharmacology of self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG), a novel siRNA nanoparticle platform". Toxicology Reports. 8: 839โ€“845. Bibcode:2021ToxR....8..839K. doi:10.1016/j.toxrep.2021.03.022. PMC 8065257 Check |pmc= value (help). PMID 33912399 Check |pmid= value (help).
  29. โ†‘ Yun, Sung-Il; Lee, Sang-Kyu; Goh, Eun-Ah; Kwon, Oh Seung; Choi, Woorim; Kim, Jangseon; Lee, Mi Sun; Choi, Soon Ja; Lim, Seung Sik; Moon, Tae Kee; Kim, Sin Hae; Kyong, Keeyeol; Nam, Gaewon; Park, Han-Oh (2022). "Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia". Scientific Reports. 12 (1): 1607. Bibcode:2022NatSR..12.1607Y. doi:10.1038/s41598-022-05544-w. PMC 8803970 Check |pmc= value (help). PMID 35102171 Check |pmid= value (help).
  30. โ†‘ Han-Oh Park ORCID Profile
  31. โ†‘ Han-Oh Park โ€“ Google Patents
  32. โ†‘ "2023 Technology Prize Winner: Park Han-oh". POSCO TJ Park Foundation. Retrieved 2025-07-03.

Retrieved from "https://en.everybodywiki.com/index.php?title=Han-Oh_Park&oldid=6338757"
License CC BY-SA 3.0
Powered by MediaWiki